WithdrawnNot Applicable

Autologous Blood Patch for Primary Spontaneous Pneumothorax

Stopped: unable to screen d/t schedule

United States0Started 2024-07

Plain-language summary

The purpose of this study is to show that treatment with prophylactic autologous blood patch (ABP) after management of primary spontaneous pneumothorax (PSP) is feasible, reduces the incidence of prolonged air leaks, and reduces hospital length of stay. An ABP is a medical procedure that uses one's own blood in order to close one or many holes identified in the lungs. The blood modulates the pressure of the lungs and forms a clot, sealing the leak. Primary spontaneous pneumothorax is an abnormal collection of air in the pleural space between the lung and the chest wall.

Who can participate

Age range13 Years – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosed with primary spontaneous pneumothorax (first occurrence) and meets criteria for chest tube placement or Diagnosed with recurrent primary spontaneous pneumothorax (recurrence) and meets criteria for blebectomy with a pleural procedure * Between the ages of 13-18 Exclusion Criteria: Known hematologic disorders Hemodynamic instability at the time of presentation

What they're measuring

Hospital Length of Stay

Timeframe: 30 days

Trial details

NCT IDNCT06088901

SponsorRush University Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-07

View on ClinicalTrials.gov More Primary Spontaneous Pneumothorax trials